COVID-19 and Sepsis
COVID-19
cytokine storm
dysregulated immune response
hyperinflammation
sepsis
multiorgan failure
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
17 12 2021
17 12 2021
Historique:
received:
24
08
2021
accepted:
29
09
2021
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
1
1
2022
Statut:
epublish
Résumé
The COVID-19 pandemic has created a major alteration in the medical literature including the sepsis discussion. From the outset of the pandemic, various reports have indicated that although there are some unique features pertinent to COVID-19, many of its acute manifestations are similar to sepsis caused by other pathogens. As a consequence, the old definitions now require consideration of this new etiologic agent, namely SARS-CoV-2. Although the pathogenesis of COVID-19 has not been fully explained, the data obtained so far in hospitalized patients has revealed that serum cytokine and chemokine levels are high in severe COVID-19 patients, similar to those found with sepsis. COVID-19 may involve multiple organ systems. In addition to the lungs, the virus has been isolated from blood, urine, faeces, liver, and gallbladder. Results from autopsy series in COVID-19 patients have demonstrated a wide range of findings, including vascular involvement, congestion, consolidation, and hemorrhage as well as diffuse alveolar damage in lung tissue consistent with acute respiratory distress syndrome (ARDS). The presence of viral cytopathic-like changes, infiltration of inflammatory cells (mononuclear cells and macrophages), and viral particles in histopathological samples are considered a consequence of both direct viral infection and immune hyperactivation. Thromboembolism and hyper-coagulopathy are other components in the pathogenesis of severe COVID-19. Although the pathogenesis of hypercoagulability is not fully understood, it has been pointed out that all three components of Virchow’s triad (endothelial injury, stasis, and hypercoagulable state) play a major role in contributing to clot formation in severe COVID-19 infection. In severe COVID-19 cases, laboratory parameters such as hematological findings, coagulation tests, liver function tests, D-dimer, ferritin, and acute phase reactants such as CRP show marked alterations, which are suggestive of a cytokine storm. Another key element of COVID-19 pathogenesis in severe cases is its similarity or association with hemophagocytic lymphohistiocytosis (HLH). SARS-CoV-2 induced cytokine storm has significant clinical and laboratory findings overlapping with HLH. Viral sepsis has some similarities but also some differences when compared to bacterial sepsis. In bacterial sepsis, systemic inflammation affecting multiple organs is more dominant than in COVID-19 sepsis. While bacterial sepsis causes an early and sudden onset clinical deterioration, viral diseases may exhibit a relatively late onset and chronic course. Consideration of severe COVID-19 disease as a sepsis syndrome has relevance and may assist in terms of determining treatments that will modulate the immune response, limit intrinsic damage to tissue and organs, and potentially improve outcome.
Identifiants
pubmed: 34590796
doi: 10.3906/sag-2108-239
pmc: PMC8771020
doi:
Substances chimiques
Chemokines
0
Cytokines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3301-3311Informations de copyright
This work is licensed under a Creative Commons Attribution 4.0 International License.
Déclaration de conflit d'intérêts
none declared
Références
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
BMJ. 2020 Sep 4;370:m3379
pubmed: 32887691
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Crit Care. 2020 Aug 12;24(1):495
pubmed: 32787909
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Infection. 2021 Feb;49(1):117-126
pubmed: 33231841
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Arch Pathol Lab Med. 2020 Dec 1;144(12):1465-1474
pubmed: 32818235
J Clin Invest. 2020 Dec 1;130(12):6409-6416
pubmed: 32809969
Ren Fail. 2020 Nov;42(1):483-488
pubmed: 32438839
Ann Intensive Care. 2020 Sep 7;10(1):119
pubmed: 32894364
Artif Organs. 2020 Sep;44(9):918-925
pubmed: 32516506
Lancet Glob Health. 2017 Feb;5(2):e157-e167
pubmed: 28104185
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
JAMA. 2020 Aug 25;324(8):739-740
pubmed: 32777028
Eur Respir Rev. 2020 Jul 21;29(157):
pubmed: 32699026
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388
pubmed: 32275452
Turk J Med Sci. 2020 Jul 19;50(8):1801-1809
pubmed: 32682358
Viruses. 2012 Jun;4(6):1011-33
pubmed: 22816037
Blood Adv. 2021 Feb 9;5(3):872-888
pubmed: 33560401
Cytokine Growth Factor Rev. 2020 Jun;53:66-70
pubmed: 32418715
Cytokine. 2021 Jan;137:155302
pubmed: 33002740
Intensive Care Med. 2016 Dec;42(12):1958-1969
pubmed: 27695884
J Innate Immun. 2017;9(5):441-455
pubmed: 28697503
Crit Rev Clin Lab Sci. 2013 Jan-Feb;50(1):23-36
pubmed: 23480440
Virchows Arch. 2020 Sep;477(3):359-372
pubmed: 32642842
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
Semin Immunopathol. 2017 Jul;39(5):517-528
pubmed: 28555385
Am J Clin Pathol. 2011 Feb;135(2):182-9
pubmed: 21228358
J Hepatol. 2020 Sep;73(3):566-574
pubmed: 32298767
Lancet Rheumatol. 2020 Jul;2(7):e393-e400
pubmed: 32835245
Crit Care Med. 2011 Aug;39(8):1886-95
pubmed: 21516036
Clin Rheumatol. 2020 Jul;39(7):2085-2094
pubmed: 32474885
Inflamm Res. 2020 Aug;69(8):757-763
pubmed: 32468151
N Engl J Med. 2003 Apr 17;348(16):1546-54
pubmed: 12700374
Rheumatol Int. 2021 Jan;41(1):7-18
pubmed: 32588191
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Kidney Int. 2020 Dec;98(6):1370-1372
pubmed: 32920023
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Turk J Med Sci. 2020 Apr 17;50(SI-1):620-632
pubmed: 32299202
Chest. 2020 Sep;158(3):1143-1163
pubmed: 32502594
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1767-1776
pubmed: 28516200
Circulation. 2020 Oct 27;142(17):1609-1611
pubmed: 32877231
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
J Cell Physiol. 2021 May;236(5):3366-3382
pubmed: 33078408
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Adv Ther. 2017 Nov;34(11):2393-2411
pubmed: 29022217
Infect Control Hosp Epidemiol. 2021 Jan;42(1):84-88
pubmed: 32703320
Crit Care Med. 1992 Jun;20(6):864-74
pubmed: 1597042
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
J Allergy Clin Immunol. 2020 Jul;146(1):213-215
pubmed: 32437739
J Thromb Haemost. 2020 Jul;18(7):1738-1742
pubmed: 32302438
Viruses. 2012 Apr;4(4):557-80
pubmed: 22590686
Chin J Traumatol. 2020 Aug;23(4):190-195
pubmed: 32690231
JAMA. 2014 Jul 2;312(1):90-2
pubmed: 24838355
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Pol Arch Intern Med. 2020 Apr 30;130(4):276-286
pubmed: 32186831
Virus Res. 2020 Aug;285:198005
pubmed: 32408156
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454
Front Immunol. 2018 Sep 27;9:2147
pubmed: 30319615